Evidence map›Paper›PMID 26670424›Full record

ArticleHuman genetics2016

Incorporation of 5-ethynyl-2'-deoxyuridine (EdU) as a novel strategy for identification of the skewed X inactivation pattern in balanced and unbalanced X-rearrangements.

Luiza Sisdelli, Angela Cristina Vidi, Mariana Moysés-Oliveira, Adriana Di Battista, Adriana Bortolai, Danilo Moretti-Ferreira, Magnus R Dias da Silva, Maria Isabel Melaragno, Gianna Carvalheira

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Human genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Whole-Genome Sequencing Identified New Structural Variations in theInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Luiza SisdelliDepartment of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, 04023-900, Brazil.
Angela Cristina VidiDepartment of Biochemistry, Universidade Federal de São Paulo, São Paulo, Brazil.
Mariana Moysés-OliveiraDepartment of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, 04023-900, Brazil.
Adriana Di BattistaDepartment of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, 04023-900, Brazil.
Adriana BortolaiDepartment of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, 04023-900, Brazil.
Danilo Moretti-FerreiraDepartment of Genetics, Instituto de Biociências de Botucatu, São Paulo State University, São Paulo, 18618-970, Brazil.
Magnus R Dias da SilvaDepartment of Biochemistry, Universidade Federal de São Paulo, São Paulo, Brazil.
Maria Isabel MelaragnoDepartment of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, 04023-900, Brazil.
Gianna CarvalheiraDepartment of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, 04023-900, Brazil. carvalheira@unifesp.br.ORCID http://orcid.org/0000-0002-6602-8319
Universidade Federal de São Paulo · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-chromosome inactivation occurs randomly in normal female cells. However, the inactivation can be skewed in patients with alterations in X-chromosome. In balanced X-autosome translocations, normal X is preferentially inactivated, while in unbalanced X alterations, the aberrant X is usually inactivated. Here, we present a novel strategy to verify the skewed X inactivation pattern through the incorporation of 5-ethynyl-2'-deoxyuridine (EdU) into cells, in 11 patients: five carriers of balanced X-autosome translocations and six of unbalanced X-chromosome alterations. Since EdU is a labeled nucleoside analog of thymidine, its incorporation during DNA synthesis can reveal late replication regions and the inactive X-chromosome. All EdU findings were validated by the human androgen receptor gene (HUMARA) assay. The late replication regions were easily and quickly visualized in all cells, where inactive Xs are marked with strong green fluorescence. It was observed that the normal X-chromosome was preferentially inactivated in patients with balanced X-autosome translocations; while the aberrant X-chromosome was inactivated in most cells from patients with unbalanced alterations. By performing the fluorescence-based EdU assay, the differences between the active and inactive X-chromosomes are more easily recognizable than by classic cytogenetic methods. Furthermore, EdU incorporation allows the observation of the late replication regions in autosomal segments present in X derivatives from X-autosome translocations. Therefore, EdU assay permits an accurate and efficient cytogenetic evaluation of the X inactivation pattern with a low-cost, easy to perform and highly reproducible technique.

Indexed as

Gene RearrangementX Chromosome InactivationChromosome DisordersChromosomes, Human, XCytogenetic AnalysisDeoxyuridineDNA ReplicationFemaleHumansMaleTranslocation, Genetic5-ethynyl-2'-deoxyuridineDeoxyuridine

Identifiers

PMID26670424
OpenAlexW2282541395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.